NCT06184399View on ClinicalTrials.gov

Efficacy, Safety and Acceptability of Ivermectin ODT in PSAC

PHASE2CompletedINTERVENTIONAL
Enrollment

260

Participants

Timeline

Start Date

June 5, 2024

Primary Completion Date

August 9, 2024

Study Completion Date

August 9, 2024

Conditions
TrichuriasisAscariasisHookworm Infections
Interventions
DRUG

Ivermectin 1.5 mg ODT

Oro-dispersible tablets of 1.5 mg ivermectin

DRUG

Ivermectin 3 mg Oral Tablet

Tablets of 3 mg ivermectin

DRUG

Albendazole 400 mg Oral Tablet

Tablets of 400 mg albendazole

DRUG

Placebo Ivermectin ODT

Placebo for ivermectin ODT

Trial Locations (1)

Unknown

Public Health Laboratory Ivo de Carneri, Chake Chake

All Listed Sponsors
collaborator

Public Health Laboratory Ivo de Carneri

OTHER

lead

Jennifer Keiser

OTHER

NCT06184399 - Efficacy, Safety and Acceptability of Ivermectin ODT in PSAC | Biotech Hunter | Biotech Hunter